Table 1. Baseline demographics and clinical characteristics.
| Variable | Febuxostat (n = 239) | Control (n = 244) |
|---|---|---|
| Sex, number (%) | ||
| Women | 49 (20.5) | 46 (18.9) |
| Men | 190 (79.5) | 198 (81.1) |
| Age, year | ||
| Mean (SD) | 69.1 (10.1) | 69.1 (10.7) |
| Median (IQR) | 70 (63–76) | 71 (63–78) |
| BMI, mean (SD), kg/m2 | 24.8 (3.9) | 25.0 (3.5) |
| Current smoker, number (%) | 28 (11.7) | 24 (9.8) |
| Blood pressure, mean (SD), mm Hg | ||
| Systolic | 128.9 (14.7) | 127.0 (15.7) |
| Diastolic | 73.3 (11.6) | 74.2 (11.4) |
| Medical history, number (%) | ||
| Hypertension | 212 (88.7) | 217 (88.9) |
| Diabetes | 85 (35.6) | 88 (36.1) |
| Dyslipidemia | 144 (60.3) | 145 (59.4) |
| Previous gouty arthritis | 6 (2.5) | 4 (1.6) |
| Myocardial infarction | 34 (14.2) | 26 (10.7) |
| PCI | 32 (13.4) | 37 (15.2) |
| CABG | 12 (5.0) | 13 (5.3) |
| Stroke | 14 (5.9) | 12 (4.9) |
| Heart failurea | 41 (17.2) | 39 (16.0) |
| Prior medication, number (%) | ||
| Any antihypertensive agent | 217 (90.8) | 222 (91.0) |
| Renin-angiotensin system inhibitorb | 156 (65.3) | 167 (68.4) |
| Calcium channel blocker | 132 (55.2) | 122 (50.0) |
| β-Blocker | 86 (36.0) | 96 (39.3) |
| Diuretic | 70 (29.3) | 70 (28.7) |
| Any lipid-reducing agent | 126 (52.7) | 129 (52.9) |
| Statins | 115 (48.1) | 124 (50.8) |
| Ezetimibe | 10 (4.2) | 6 (2.5) |
| Any antiplatelet agent | 96 (40.2) | 108 (44.3) |
| Aspirin | 77 (32.2) | 88 (36.1) |
aInvestigator reported.
bAngiotensin converting enzyme inhibitor or angiotensin receptor blocker.
Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; IQR, interquartile range; PCI, percutaneous coronary intervention